Drugs / NanoDoce
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03636256 | Apr 2019 → Nov 2021 | urinary bladder cancer, urothelial carcinoma | NanOlogy, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanoDoce | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03636256 ↗ |
| Route | Other | “NanoDoce injected into the index tumor resection site on the bladder wall” NCT03636256 ↗ |